{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:49:15Z","timestamp":1773053355092,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000894","name":"Spinal Muscular Atrophy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000894","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.nmd.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:46:56Z","timestamp":1693010816000},"page":"845-855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-8982","authenticated-orcid":false,"given":"Thanneer Malai","family":"Perumal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Pointeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Lipsmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Sprengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Czech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia A.","family":"Chiriboga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.07.008_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2023.07.008_bib0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.07.008_bib0003","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2023.07.008_bib0004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.07.008_bib0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/acn3.406","article-title":"Longitudinal characterization of biomarkers for spinal muscular atrophy","volume":"4","author":"Bonati","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0006","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2023.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.nmd.2023.07.008_bib0008","unstructured":"US Food & Drug Administration. FDA approves first drug for spinal muscular atrophy. 2016 [cited 2023 January 24]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy."},{"key":"10.1016\/j.nmd.2023.07.008_bib0009","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation) Spinraza. 2017 [cited 2023 January 24]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-spinraza_en.pdf."},{"key":"10.1016\/j.nmd.2023.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0011","unstructured":"US Food & Drug Administration. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. 2019 [cited 2023 January 24]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"10.1016\/j.nmd.2023.07.008_bib0012","unstructured":"European Medicines Agency. New gene therapy to treat spinal muscular atrophy (corrected). 2020 [cited 2023 January 24]; Available from: https:\/\/www.ema.europa.eu\/en\/news\/new-gene-therapy-treat-spinal-muscular-atrophy-corrected."},{"key":"10.1016\/j.nmd.2023.07.008_bib0013","unstructured":"US Food & Drug Administration. FDA approves oral treatment for spinal muscular atrophy. 2020 [cited 2023 January 24]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy."},{"key":"10.1016\/j.nmd.2023.07.008_bib0014","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmd.2023.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0017","unstructured":"Roche. Roche's risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy. 2019 [cited 2023 January 24]; Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2019-11-11.htm."},{"key":"10.1016\/j.nmd.2023.07.008_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0019","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure scale for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.07.008_bib0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0021","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.07.008_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation","volume":"7","author":"Main","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0023","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172346","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool","volume":"12","author":"Ramsey","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.07.008_bib0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.07.008_bib0026","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JND-180301","article-title":"Evaluator training and reliability for SMA global nusinersen trials1","volume":"5","author":"Glanzman","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.07.008_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/diagnostics11071275","article-title":"Digital biomarkers for neuromuscular disorders: a systematic scoping review","volume":"11","author":"Youn","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.nmd.2023.07.008_bib0028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000477383","article-title":"The first frontier: digital biomarkers for neurodegenerative disorders","volume":"1","author":"Dorsey","year":"2017","journal-title":"Digit Biomark"},{"key":"10.1016\/j.nmd.2023.07.008_bib0029","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/dmcn.94_12887","article-title":"Role of motivation on performance of the 6-minute walk test in boys with Duchenne muscular dystrophy","volume":"57","author":"Alfano","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpeds.2018.02.073","article-title":"Learning and encouragement effects on six-minute walking test in children","volume":"198","author":"Morales Mestre","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2023.07.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124763","article-title":"Motor performance assessment in Parkinson's disease: association between objective in-clinic, objective in-home, and subjective\/semi-objective measures","volume":"10","author":"Toosizadeh","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.07.008_bib0032","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.23937","article-title":"Rasch analysis of clinical outcome measures in spinal muscular atrophy","volume":"49","author":"Cano","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.07.008_bib0033","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/mds.26021","article-title":"Clinical trials in Huntington\u2019s disease: interventions in early clinical development and newer methodological approaches","volume":"29","author":"Sampaio","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.nmd.2023.07.008_bib0034","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.2196\/mental.3889","article-title":"Utilizing a personal smartphone custom app to assess the Patient Health Questionnaire-9 (PHQ-9) depressive symptoms in patients with major depressive disorder","volume":"2","author":"Torous","year":"2015","journal-title":"JMIR Ment Health"},{"key":"10.1016\/j.nmd.2023.07.008_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2021.662811","article-title":"Wearable, environmental, and smartphone-based passive sensing for mental health monitoring","volume":"3","author":"Sheikh","year":"2021","journal-title":"Front Digit Health"},{"key":"10.1016\/j.nmd.2023.07.008_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamacardio.2016.4395","article-title":"Feasibility of obtaining measures of lifestyle from a smartphone app: the MyHeart Counts cardiovascular health study","volume":"2","author":"McConnell","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.11","article-title":"The mPower study, Parkinson disease mobile data collected using ResearchKit","volume":"3","author":"Bot","year":"2016","journal-title":"Scientific Data"},{"key":"10.1016\/j.nmd.2023.07.008_bib0038","doi-asserted-by":"crossref","first-page":"23168","DOI":"10.3390\/s150923168","article-title":"Performance evaluation of smartphone inertial sensors measurement for range of motion","volume":"15","author":"Mourcou","year":"2015","journal-title":"Sensors"},{"key":"10.1016\/j.nmd.2023.07.008_bib0039","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neuropsychologia.2010.11.016","article-title":"Visuomotor integration deficits precede clinical onset in Huntington's disease","volume":"49","author":"Say","year":"2011","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.nmd.2023.07.008_bib0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0041","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41746-020-0260-4","article-title":"Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs)","volume":"3","author":"Goldsack","year":"2020","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0042","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaneurol.2018.0809","article-title":"Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score","volume":"75","author":"Zhan","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0043","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/mds.27376","article-title":"Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial","volume":"33","author":"Lipsmeier","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.nmd.2023.07.008_bib0044","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12984-016-0136-7","article-title":"A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease","volume":"13","author":"Godinho","year":"2016","journal-title":"J Neuroeng Rehabil"},{"key":"10.1016\/j.nmd.2023.07.008_bib0045","article-title":"A smartphone sensor-based digital outcome assessment of multiple sclerosis","author":"Montalban","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.nmd.2023.07.008_bib0046","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41746-021-00401-y","article-title":"Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis","volume":"4","author":"Pham","year":"2021","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0047","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00415-016-8334-6","article-title":"Continuous daily assessment of multiple sclerosis disability using remote step count monitoring","volume":"264","author":"Block","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0048","doi-asserted-by":"crossref","first-page":"e18160","DOI":"10.2196\/18160","article-title":"Symbol digit modalities test variant in a smartphone app for persons with multiple sclerosis: validation study","volume":"8","author":"van Oirschot","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.nmd.2023.07.008_bib0049","unstructured":"ClinicalTrials.gov. A study of risdiplam (RO7034067) in adult and pediatric participants with spinal muscular atrophy (Jewelfish). [cited 2023 January 24]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03032172."},{"key":"10.1016\/j.nmd.2023.07.008_bib0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","article-title":"Forming inferences about some intraclass correlation coefficients","volume":"1","author":"McGraw","year":"1996","journal-title":"Psychol Methods"},{"key":"10.1016\/j.nmd.2023.07.008_bib0051","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120059","article-title":"Development of the SMA independence scale\u2013upper limb module (SMAIS\u2013ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA","volume":"432","author":"Trundell","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2023.07.008_bib0053","unstructured":"ClinicalTrials.gov. A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). [cited 2023 January 24]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02240355."},{"key":"10.1016\/j.nmd.2023.07.008_bib0054","unstructured":"US Food & Drug Administration. Highlights of prescribing information. 2019 [cited 2023 January 24]; Available from: https:\/\/www.fda.gov\/media\/126109\/download."},{"key":"10.1016\/j.nmd.2023.07.008_bib0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000517411","article-title":"First regulatory qualification of a novel digital endpoint in duchenne muscular dystrophy: a multi-stakeholder perspective on the impact for patients and for drug development in neuromuscular diseases","volume":"5","author":"Servais","year":"2021","journal-title":"Digit Biomark"},{"key":"10.1016\/j.nmd.2023.07.008_bib0056","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41746-020-0305-8","article-title":"Outcome measures based on digital health technology sensor data: data- and patient-centric approaches","volume":"3","author":"Taylor","year":"2020","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.nmd.2023.07.008_bib0057","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","article-title":"Clinical trials in rare disease: challenges and opportunities","volume":"28","author":"Augustine","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.07.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.07.008_bib0059","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.nmd.2023.07.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030710","article-title":"Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study","volume":"9","author":"Guthrie","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.nmd.2023.07.008_bib0063","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s10072-021-05396-8","article-title":"How to manage with telemedicine people with neuromuscular diseases?","volume":"42","author":"Spina","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2023.07.008_bib0064","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2589-7500(19)30111-6","article-title":"Bridging the digital divide in health care","volume":"1","author":"Makri","year":"2019","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.nmd.2023.07.008_bib0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5455\/medarh.2014.68.57-60","article-title":"Patient monitoring in mobile health: opportunities and challenges","volume":"68","author":"Mohammadzadeh","year":"2014","journal-title":"Med Arch"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:40:53Z","timestamp":1717540853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0960896623001797"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.07.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}